戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 gadopentetate dimeglumine), and 1.91 nmol/g (gadobenate dimeglumine).
2 h gadoxetate disodium and 204 performed with gadobenate dimeglumine.
3 gnificantly more often than with intravenous gadobenate dimeglumine.
4 ol/L gadopentetate dimeglumine and 0.5 mol/L gadobenate dimeglumine.
5 = 97; 8 mL, n = 1; 16 mL, n = 1] and 99 with gadobenate dimeglumine [0.1 mmol per kilogram of body we
6 gher rate with gadoxetate disodium than with gadobenate dimeglumine (10.7% [37 of 345 examinations] v
7 fter gadoxetate disodium administration than gadobenate dimeglumine (14% [14 of 99] vs 5% [five of 99
8 etate disodium, 16.6 mL vs 16.6 mL, P = .99; gadobenate dimeglumine, 18.0 mL vs 17.8 mL, P = .77) and
9 ratory motion-related artifact compared with gadobenate dimeglumine (39% vs 10%, P < .0001) and of ne
10 st media (gadopentetate dimeglumine, 31 540; gadobenate dimeglumine, 66 152; other, 7915).
11 BCA (gadodiamide, gadopentetate dimeglumine, gadobenate dimeglumine), a macrocyclic GBCA (gadobutrol,
12 sion In patients receiving multiple doses of gadobenate dimeglumine, a linear relationship existed be
13 graphy (0.2 mmol per kilogram of body weight gadobenate dimeglumine administered at a rate of 2.0 mL
14 umine, a linear relationship existed between gadobenate dimeglumine administrations and an increase i
15 mine and SI change at MRI following multiple gadobenate dimeglumine administrations.
16 ailure developed NSF after administration of gadobenate dimeglumine after more than 2 years' mean fol
17                                              Gadobenate dimeglumine and gadopentetate dimeglumine wer
18     Following the switch from gadodiamide to gadobenate dimeglumine and gadopentetate dimeglumine, an
19 ant difference of 3.1 msec was noted between gadobenate dimeglumine and placebo (95% CI: -1.8, 8.0) a
20                                              Gadobenate dimeglumine and saline placebo were injected
21  evaluate the relationship between dosage of gadobenate dimeglumine and SI change at MRI following mu
22 ically approved Gd chelate, Multihance((R)) (gadobenate dimeglumine), and a novel experimental liposo
23  contrast agents (gadopentetate dimeglumine, gadobenate dimeglumine, and gadofosveset trisodium) dilu
24 ween the four GBCAs gadodiamide, gadobutrol, gadobenate dimeglumine, and gadoterate meglumine, and to
25 ndergone three or more MRI examinations with gadobenate dimeglumine, and had the baseline scan and an
26                         Therefore, half-dose gadobenate dimeglumine at 3-T MR imaging may be sufficie
27 GBCAs (gadoterate meglumine, gadobutrol, and gadobenate dimeglumine) at 0.1 mmol/kg.
28  and outperform a commercial Gd-based agent (gadobenate dimeglumine) by more than eight-fold at physi
29 t were significantly worse than those in the gadobenate dimeglumine cohort (P < .005).
30 nificantly (P <.05) superior enhancement for gadobenate dimeglumine compared with that for gadopentet
31 g brain tumors was achieved with 0.1 mmol/kg gadobenate dimeglumine compared with that with 0.1 mmol/
32 tration of the linear agents gadodiamide and gadobenate dimeglumine compared with the macrocyclic age
33                                              Gadobenate dimeglumine dose was weight based (0.1 mmol p
34                    Ninety patients underwent gadobenate dimeglumine-enhanced abdominal magnetic reson
35  and group 2 included patients who underwent gadobenate dimeglumine-enhanced MR imaging.
36 le gadodiamide-enhanced studies but not with gadobenate dimeglumine-enhanced studies, likely reflecti
37 SI was found between half-dose and full-dose gadobenate dimeglumine-enhanced synovial tissue (mean: 9
38 e data sets for gadoxetate disodium than for gadobenate dimeglumine for both the general population (
39 synthesis was stimulated by gadoversetamide, gadobenate dimeglumine, gadodiamide, and gadopentetate d
40                     Injection of 0.2 mmol/kg gadobenate dimeglumine has no detrimental effect on card
41                            Published data on gadobenate dimeglumine have been somewhat contradictory.
42 d to gadodiamide and one had been exposed to gadobenate dimeglumine in addition to gadodiamide.
43  of 549 cases of abdominal MRI with low-dose gadobenate dimeglumine in liver transplant recipients at
44 d occurs significantly more often than after gadobenate dimeglumine in patients who received both con
45 ium per gram of tissue (95% CI: 3.5, 6.1) in gadobenate dimeglumine-injected rats, and 6.9 mug gadoli
46 re noted in seven of 47 (15%) subjects after gadobenate dimeglumine injection and in five of 47 (11%)
47 pective of baseline renal function, MRI with gadobenate dimeglumine is a nonnephrotoxic imaging modal
48                                              Gadobenate dimeglumine may be safe in this population.
49 gadoversetamide (n = 6), gadobutrol (n = 1), gadobenate dimeglumine (n = 1), multiple (n = 41), and u
50 te meglumine), linear GBCAs (gadodiamide and gadobenate dimeglumine), or saline.
51 llowing the administration of 134 mL +/- 141 gadobenate dimeglumine over 55 months +/- 35.2.
52          Significant (P <.05) preference for gadobenate dimeglumine over gadopentetate dimeglumine wa
53                        The reaction rate for gadobenate dimeglumine peaked (maximum per quarter, 0.38
54                                              Gadobenate dimeglumine phantoms with a wide range of T1
55 patobiliary-specific GBCAs, Gd-EOB-DTPA, and gadobenate dimeglumine, primarily though OATP transporte
56 oversetamide, gadopentetate dimeglumine, and gadobenate dimeglumine) produced a maximum stimulation o
57 ean increase of 0.015% +/- 0.004 per 1 mL of gadobenate dimeglumine (R(2) = 0.3, P < .001).
58                                    The final gadobenate dimeglumine reaction rate (last 3 quarters, 0
59 suggest gadolinium deposition in the DN with gadobenate dimeglumine use, although it is considerably
60                                              Gadobenate dimeglumine was associated with significantly
61                       Similar preference for gadobenate dimeglumine was noted by off-site readers and
62 and the on-site investigators, respectively, gadobenate dimeglumine was preferred in 13, 17, and 16 p
63  assessed 2 years before and 3.5 years after gadobenate dimeglumine was substituted for gadopentetate
64                                        After gadobenate dimeglumine was substituted for gadopentetate
65 ubgroup analysis was performed to assess the gadobenate dimeglumine washout since the last gadolinium
66 n of 0.2 mmol per kilogram of body weight of gadobenate dimeglumine, with 19 patients receiving contr
67  ratio increased linearly with the amount of gadobenate dimeglumine, with a mean increase of 0.015% +